Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
To reveal the genetic determinants of the treatment outcome of escitalopram in depressed
patients (by using candidate gene approach and whole genome scanning).